The Challenge
Curia retained PharmaBioSource as its exclusive consultant to divest its small molecule API manufacturing site and contract development and manufacturing business in Lodi, Italy, near Milan.
The Solution
PharmaBioSource marketed the site and CDMO business to strategic acquirers.
Services provided by the PharmaBioSource team:
- Benchmark valuation
- Buyer target identification and engagement
- Creation of the Confidential Information Memorandum (CIM)
- Data room development
- Due diligence support
- Negotiations and closing support
The Results
PharmaBioSource identified LIVIA Group (LIVIA International Ventures & Investment Activities), a global industrial holding and private investment firm, as the acquirer. LIVIA incorporated the Lodi site into its portfolio small molecule API CDMO company, Archimica.
What We Did
Sell-Side Advisory
Facility Divestiture